181 results on '"Mouri, Atsuto"'
Search Results
2. Prognostic significance of LAT1 expression in pleural mesothelioma
3. Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
4. Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer
5. Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer
6. Prospective assessment using 18F-FDG PET/CT as a novel predictor for early response to PD-1 blockade in non-small-cell lung cancer
7. Clinical Outcome of Nivolumab plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab
8. Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non‑small cell lung cancer treated with immunotherapy
9. Progression to Lymph Node Metastasis After Spontaneous Regression of Pulmonary Adenocarcinoma Following Biopsy
10. Clinicopathological impact of VEGFR2 and VEGF‐C in patients with EGFR‐major mutant NSCLC receiving osimertinib
11. A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress)
12. Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%
13. A Case of Malignant Pleural Mesothelioma with Prolonged Survival Achieved by Multiple Sessions of Palliative Radiotherapy
14. Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer
15. Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer
16. Additional file 2 of Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer
17. Additional file 1 of Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer
18. Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy
19. Metachronous lesions in the orbit, retroperitoneum, and pleura of mucosa‐associated lymphoid tissue lymphoma: A case report
20. Pembrolizumab-induced esophagitis dissecans superficialis in a patient with squamous cell lung carcinoma
21. MO4-4 Safety of immune checkpoint blockade in lung cancer and pre-existing autoimmune diseases: NEJ047 multi-center study
22. Real‐world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive‐disease small‐cell lung cancer
23. Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non‐small cell lung cancer
24. Survey of malignant pleural mesothelioma treatment in Japan: Patterns of practice and clinical outcomes in tomotherapy facilities
25. Primary malignant pericardial mesothelioma in a patient with a history of thoracic radiotherapy and asbestos exposure: A case report
26. O2-6-2 - Progression-free duration of NSCLC patients after cessation of Nivolumab
27. Real‐world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive‐disease small‐cell lung cancer.
28. Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status
29. Salvage Chemotherapy in Patients with Previously Treated Thymic Carcinoma
30. Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs
31. Pretreatment Glasgow prognostic score predicts survival among patients with high PD‐L1 expression administered first‐line pembrolizumab monotherapy for non‐small cell lung cancer
32. Tumor immunity is related to 18 F‐FDG uptake in thymic epithelial tumor
33. Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B)
34. Prospective assessment using 18F-FDG PET/CT as a novel predictor for early response to PD-1 blockade in non-small-cell lung cancer.
35. Synchronous dilemma of sarcoid-like reaction and drastic response after PD-1 blockade administration in lung cancer
36. Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers
37. Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study
38. Clinical impact of post‐progression survival on overall survival in patients receiving nivolumab monotherapy as a second‐line treatment for advanced non‐small cell lung cancer
39. Effectiveness of EGFR‐TKI rechallenge immediately after PD ‐1 blockade failure
40. Pre‐existing interstitial lung disease does not affect prognosis in non‐small cell lung cancer patients with PD‐L1 expression ≥50% on first‐line pembrolizumab
41. A case of cerebral infarction due to pleomorphic carcinoma of the lung
42. Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non‐small cell lung cancer harboring EGFR mutation
43. Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events
44. Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer
45. Evaluation of a chest rehabilitation project in Nepal using the St. George’s Respiratory Questionnaire and Chronic Obstructive Pulmonary Disease Assessment Test
46. Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review
47. Tumor immunity is related to 18F‐FDG uptake in thymic epithelial tumor.
48. Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab
49. Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer
50. Clinical significance of primary prophylactic pegylated‐granulocyte‐colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non‐small cell lung cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.